Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05515991

Symptom Management in Patients on Dialysis

This is a parallel arm, pilot study used to examine the feasibility of electronic patient reported outcome measures (ePROMs) for symptom assessment and monitoring as well as a linked self-management support and decision support information hub (https://symptomcare.org) to facilitate symptom management for patients on maintenance hemodialysis.

Two dialysis centers will be included in the study, with one center receiving SUPPORT-Dialysis (intervention arm) and the other receiving standard care (control arm).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Etobicoke General Hospital, Brampton, Ontario, Canada

Loading trial locations.

About this study

In Canada, 20,000-25,000 patients with end-stage kidney disease (ESKD) experience a range of symptoms such as chronic pain, itchiness, fatigue, anxiety, depression and sleep disturbances [1-5]. These may impact quality of life, increase mortality, decrease treatment adherence, and increased hospitalizations [6-8]. These symptoms are under-managed and under-recognized among these patients, but screening and managing symptoms using patient reported outcomes measures (PROMs) may be a useful and inexpensive solution. PROMS have previously been used successfully in cancer care [8-9], and have potential for clinical care of patients with kidney failure as well.

Electronic collection of PROMs (ePROMs) facilitates PROMs use by allowing linkage to electronic patient records [10-11] and immediate scoring and presentation of results to patients and clinicians [12-14]. ePROMs allow the use of computer adaptive testing (CAT) to personalize questions, increase the precision of measurements and reduce survey burden [15-17]. The investigators also developed a self-management support and decision support resource hub(https://symptomcare.org) to help dialysis patients and their clinical team in identifying and managing relevant physical and psychological symptoms that require further assessment and potential intervention.

Patients will complete Patient Reported Outcome Measurement Information System (PROMIS) CAT surveys on an electronic data capture system (SUPPORT-Dialysis) every four weeks during their dialysis treatment for six months. In the intervention, patients with moderate/severe symptoms will be flagged for the clinical team. Moderate/severe symptoms will be determined based on whether the participants score above a pre-defined cut-off in the surveys. The participant, primary nurse, and nephrologist will also receive an output report and be given access to https://symptomcare.org for suggested symptom management actions.

To establish the feasibility and acceptability of the intervention, the investigators will assess

  • Recruitment Rate
  • Retention and Completion rate
  • Acceptability
  • Patient satisfaction
  • Staff satisfaction

Based on the objectives of this study, the investigators hypothesize the following:

  • Recruitment goals will be met; >50% of approached patients will consent; completion rate will be > 80% of participants at least 50% of the time, and dropout rate will be < 30%.
  • >80% of patients find the toolkit acceptable; <20% of staff find the process intrusive to workflow.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing maintenance hemodialysis for more than 3 months

Exclusion criteria

  • Patients with severe acute illness or condition that hampers questionnaire completion assessed by clinical team.
  • Dementia indicated in the medical record, indicated by the managing healthcare team.
  • Unable to understand English - as assessed by clinical team.
  • Life expectancy < 6 months as assessed by main responsible nephrologist.
  • Unwilling or unable to provide informed consent.

Treatment and study plan

SUPPORT-DIALYSIS with Access to Output Report and Information Hub

Other

SUPPORT-Dialysis is a symptom assessment response toolkit, consisting of a screening and response component. Participants will be screened for symptoms and distress using an electronic assessment(ePROMs). Output reports based on ePROMs scores will be provided to patients as well as the clinical care team.

Participants at Toronto General Hospital will complete the screening every 4 weeks for 6 months, and each time the output report will be provided to both patients and the clinical team.The second, response component of the intervention is the information support and self-management hub (https://symptomcare.org). All participants and the clinical team will be given access to this website, which provides information about self-management for patients as well as management advice for healthcare professionals.

SUPPORT-DIALYSIS Only

Other

SUPPORT-Dialysis screening will also be implemented at Humber River Hospital, but participants and clinical team will not be receiving the output screening report or be given access to the information hub with symptom management resources.

Primary outcomes

  1. Recruitment Target

    Time frame: Baseline

    Feasibility of toolkit will be confirmed if recruitment target of 30 participants at each site are obtained in a 3-month period of the pilot.

  2. Proportion of Eligible Patients who decline consent

    Time frame: Baseline

    Feasibility of toolkit will be confirmed if decline rate is <50% for eligible patients.

  3. Proportion of Participants who miss or refuse ePROMs follow-ups

    Time frame: Baseline to follow-up (6 months)

    Feasibility of toolkit will be confirmed if <30% of participants complete <50% of all follow-up visits.

  4. Proportion of Enrolled Patients who Drop-Out From the Study

    Time frame: Baseline to follow-up (6 months)

    Feasibility of toolkit will be confirmed if the dropout rate is < 30%.

Secondary outcomes

  1. Patient Acceptability

    Time frame: Follow-up (every 4 weeks, up to 6 months)

    Proportion of patients who find the tool 1) acceptable, 2) not burdensome and 3) important, based on responses to the "Patient Satisfaction Survey" they will complete.

  2. Clinical Team Acceptability

    Time frame: Follow-up (every 4 weeks, up to 6 months)

    Proportion of staff who do not find the use of the tool intrusive to the workflow, based on responses to the "Staff Satisfaction Survey" they will complete.

Other outcomes

  1. Incidence Rate of Healthcare Use

    Time frame: Baseline to Follow-up (6 months)

    Patients will complete the 'Healthcare Use Questionnaire' at each follow-up visit. Incidence rate of healthcare use will be determined via incidence of hospitalization and emergency visits every 4 weeks.

  2. Physical Health Component Score

    Time frame: Baseline to Follow-up (6 months)

    Measured by the 36-Item Kidney Disease Quality of Life Instrument (KDQOL-36) and the 12-Item Short Form Health Survey (SF-12) embedded in ePROMs. SF-12 is a part of KDQOL-36, specifically items 1-12. Scoring wise, items 1, 8, & 12-36 have a minimum value of 1 and maximum value of 5. Items 2 & 3 have a minimum value of 1 and maximum value of 3. Items 4-7 have a minimum value of 1 and maximum value of 2. Items 9-11 have a minimum value of 1 and maximum value of 6. Whether higher or lower scores determine better outcomes depends on the item.

  3. Mental Health Component Score

    Time frame: Baseline to Follow-up (6 months)

    Measured by the 36-Item Kidney Disease Quality of Life Instrument (KDQOL-36) and the 12-Item Short Form Health Survey (SF-12) embedded in ePROMs. SF-12 is a part of KDQOL-36, specifically items 1-12. Scoring wise, items 1, 8, & 12-36 have a minimum value of 1 and maximum value of 5. Items 2 & 3 have a minimum value of 1 and maximum value of 3. Items 4-7 have a minimum value of 1 and maximum value of 2. Items 9-11 have a minimum value of 1 and maximum value of 6. Whether higher or lower scores determine better outcomes depends on the item.

  4. Kidney Disease Quality of Life

    Time frame: Baseline to Follow-up (6 months)

    Measured by the 36-Item Kidney Disease Quality of Life Instrument (KDQOL-36). Scoring wise, items 1, 8, & 12-36 have a minimum value of 1 and maximum value of 5. Items 2 & 3 have a minimum value of 1 and maximum value of 3. Items 4-7 have a minimum value of 1 and maximum value of 2. Items 9-11 have a minimum value of 1 and maximum value of 6. Whether higher or lower scores determine better outcomes depends on the item.

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Collaborators

  • Humber River Hospital

Registry information

Official study title

Assessing the Feasibility of Self-reported MeasUrement of Physical and PsychosOcial Symptoms and Response Tool in Patients on Dialysis- Pilot Study

Important dates

Study start
2023
Primary completion
2024
Study completion
2025
First posted
Aug 25, 2022
Registry last updated
May 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.